United States


TSRO.OQ on NASDAQ Stock Exchange Global Select Market

24 Feb 2017
Change (% chg)

$0.96 (+0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for TSRO.OQ


TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including... (more)


Beta: 1.53
Market Cap(Mil.): $9,930.44
Shares Outstanding(Mil.): 53.41
Dividend: --
Yield (%): --


  TSRO.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -7.18 -- --
ROI: -72.19 -3.18 12.94
ROE: -100.06 5.86 14.09

Deals of the day-Mergers and acquisitions

Feb 8 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:

Feb 08 2017

Exclusive: Cancer drugmaker Tesaro attracts takeover interest - sources

U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter.

Feb 08 2017

BRIEF-Tesaro announces opening of Niraparib expanded access program for U.S. patients with ovarian cancer

* Tesaro announces opening of niraparib expanded access program for u.s. Patients with ovarian cancer

Jan 17 2017

BRIEF-Tesaro receives complete response letter for Rolapitant IV from U.S. FDA

* Tesaro receives complete response letter for Rolapitant IV from U.S. FDA

Jan 11 2017

BRIEF-Tesaro expects to have sold about 9,165 Varubi units in quarter ended Dec. 31

* Sees total number of units of Varubi sold by company in quarter ended December 31, 2016 were approximately 9,165 units Source text - (http://bit.ly/2iZWOWx) Further company coverage:

Jan 09 2017

Clovis's ovarian cancer drug wins accelerated FDA approval

The U.S. Food and Drug Administration granted accelerated approval to Clovis Oncology Inc's ovarian cancer drug in patients with a specific gene mutation whose disease had advanced despite two or more rounds of chemotherapy.

Dec 19 2016

BRIEF-Tesaro announces pricing of public offering of common stock

* Priced an underwritten public offering of an aggregate of 1.75 million shares of common stock at offering price to public of $135.00/share

Nov 15 2016

BRIEF-Tesaro announces third-quarter 2016 operating results

* Tesaro Inc says pre-launch planning ongoing to support four potential product launches in 2017 across U.S. and Europe

Nov 03 2016

BRIEF-Tesaro announces submission of niraparib new drug application

* Tesaro announces submission of niraparib new drug application for platinum-sensitive, recurrent ovarian cancer Source text for Eikon: Further company coverage:

Nov 01 2016

BRIEF-Tesaro and Zai Lab announce collaboration, development and license agreement

* Tesaro and zai lab announce collaboration, development and license agreement

Sep 29 2016

More From Around the Web

Earnings vs. Estimates